ProfileGDS5678 / 1436631_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 65% 72% 69% 67% 48% 60% 61% 72% 70% 71% 75% 72% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9170375
GSM967853U87-EV human glioblastoma xenograft - Control 23.9011965
GSM967854U87-EV human glioblastoma xenograft - Control 34.5900872
GSM967855U87-EV human glioblastoma xenograft - Control 44.3415769
GSM967856U87-EV human glioblastoma xenograft - Control 54.0567567
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2192948
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6705460
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6684961
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.5729172
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.353170
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4433571
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9394875
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6347472
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1203968